Abstract Number: 2385 • 2014 ACR/ARHP Annual Meeting
Reasons for Non-Vaccination in Rheumatoid Arthritis and Spondyloarthritis Patients
Background/Purpose: Patients with inflammatory rheumatic diseases are at increased risk of infections when compared to healthy controls. Despite the fact that part of these infections…Abstract Number: 2386 • 2014 ACR/ARHP Annual Meeting
Patients’ Interpretations of Rheumatoid Arthritis Model Disease States in a Safety-Net Rheumatology Clinic
Background/Purpose: Patient assessment of disease activity (PtGA) measured by visual analog scale (VAS) is often a barrier to patients achieving remission in rheumatoid arthritis (RA).…Abstract Number: 2387 • 2014 ACR/ARHP Annual Meeting
Relation Between Disease Activity Indices and Their Individual Components and Radiographic Progression in Rheumatoid Arthritis: A Systematic Literature Review
Background/Purpose: Composite indices and single items are available to monitor disease activity in rheumatoid arthritis (RA). Their relation to radiographic progression is an important aspect…Abstract Number: 2388 • 2014 ACR/ARHP Annual Meeting
DMARD Use after an Initial Acute MI Is Associated with Reduced Risk of a Recurrent Event and Mortality
Background/Purpose Previous studies have suggested that disease modifying anti-rheumatic drugs (DMARDs) may reduce cardiovascular risk among patients with rheumatoid arthritis (RA). This analysis examined whether…Abstract Number: 2389 • 2014 ACR/ARHP Annual Meeting
MRI Osteitis at Baseline Predicts the Development of Rapid Radiographic Progression at 1 Year Toward Patients with Early-Stage Rheumatoid Arthritis
Background/Purpose: EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis (RA) states that magnetic resonance imaging (MRI)…Abstract Number: 2390 • 2014 ACR/ARHP Annual Meeting
Determinants and Impact of Early Initiation of Disease-Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis
Background/Purpose Early initiation of disease-modifying anti-rheumatic drug (DMARD) therapy is recommended to improve rheumatoid arthritis (RA) outcomes. The aim of this study was to determine…Abstract Number: 2391 • 2014 ACR/ARHP Annual Meeting
Sustained Rheumatoid Arthritis Remission and Low Disease Activity: Analysis of 13 Years of Follow up in Clinical Practice
Background/Purpose Biological therapies (BTs) have greatly improved the outcomes in RA patients and nowadays clinical remission (REM) and low disease activity (LDA) have become realistic…Abstract Number: 2392 • 2014 ACR/ARHP Annual Meeting
Anti-Carbamylated Antibodies (anti-CarPA) Are Associated with Long Term Disability and Increased Disease Activity in Patients with Early Inflammatory Arthritis: Results from the Norfolk Arthritis Register (NOAR)
Background/Purpose: Anti-CarPA have been shown to predict development of rheumatoid arthritis (RA) in patients with arthralgia. However, little is known about their association with disease…Abstract Number: 2353 • 2014 ACR/ARHP Annual Meeting
The Nitric Oxide Receptor Soluble Guanylyl Cyclase Is Found in Lymphatic Vessels of Arthritic Mice and Inhibition Alters Lymphatic Pulse
Background/Purpose: Rheumatoid arthritis (RA) is a chronic erosive inflammatory condition that is characterized by episodes of “flare” due to synovitis of an affected joint. It…Abstract Number: 2354 • 2014 ACR/ARHP Annual Meeting
Efficacy of a Novel Orally Bioavailable JAK1 Selective Compound in a Preclinical Rat Collagen-Induced Arthritis Model
Background/Purpose Janus kinase (JAK) is a family of four tyrosine kinases that play a critical role in cytokine signaling and downstream lymphocyte activation and function. …Abstract Number: 2355 • 2014 ACR/ARHP Annual Meeting
Apremilast, a Novel Phosphodiesterase 4 Inhibitor, and Methotrexate Independently Prevent Inflammation in Vivo and in Vitro
Background/Purpose Phosphodiesterase 4 (PDE4) inhibitors have clear immunoregulatory effects in laboratory studies, and the clinical application of this class of drug in the field of…Abstract Number: 2356 • 2014 ACR/ARHP Annual Meeting
Toluenesulfonylamido-Chalcone, 4-(p-toluenesulfonylamido)-4-Hydroxychalcone (TSAHC) Suppresses Inflammatory Response and Joint Destruction in an Experimental Arthritic Mice and Fibroblast-like Synoviocytes
Background/Purpose TSAHC, a toluenesulfonylamido-chalcone, 4-(p-toluenesulfonylamido)-4-hydroxychalcone is a compound to block proliferation and metastatic potential of cancer cells. Fibroblast-like synoviocytes of rheumatoid arthritis (RA-FLS) have inflammatory…Abstract Number: 2357 • 2014 ACR/ARHP Annual Meeting
Vascular Adhesion Molecule-1 Overexpression in Collagen-Induced Arthritis: Modeling Vascular Dysfunction in Rheumatoid Arthritis
Vascular adhesion molecule-1 Overexpression in collagen-induced arthritis: modeling vascular dysfunctionS in rheumatoid arthritis Background/Purpose: Rheumatoid Arthritis (RA) patients are at risk of developing primary coronary…Abstract Number: 2358 • 2014 ACR/ARHP Annual Meeting
The Role of Dendritic Cells during Inflammatory Arthritis
Background/Purpose Dendritic cells (DCs) play an important role in bridging the innate and the adaptive immune response by serving as antigen presenting cells and are…Abstract Number: 2359 • 2014 ACR/ARHP Annual Meeting
CGEN-15001, a Novel Immunomodulatory Fusion Protein of the B7 Family Induces Immune Tolerance and Shows Efficacy in Mouse Models of Rheumatoid Arthritis and Psoriasis
Background/Purpose CGEN-15001 is an Fc-fusion protein consisting of the extracellular domain of a novel B7-like protein, discovered based on shared family characteristics. CGEN-15001 inhibits T…
ACR Meeting Abstracts